Mancini Federica, Degli Esposti Lorenzo, Adamiano Alessio, Modica Jessica, Catalucci Daniele, Mehn Dora, Geiss Otmar, Iafisco Michele
Institute of Science, Technology and Sustainability for Ceramics (ISSMC), National Research Council (CNR), 48018 Faenza, Italy.
IRCCS Humanitas Research Hospital, Humanitas Cardio Center, 20089 Rozzano, Italy.
Nanomaterials (Basel). 2025 Jan 9;15(2):94. doi: 10.3390/nano15020094.
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, highliting the urgent need for new therapeutic strategies. Peptide-based therapies have demonstrated significant potential for treating CVDs; however, their clinical application is hindered by their limited stability in physiological fluids. To overcome this challenge, an effective drug delivery system is essential to protect and efficiently transport peptides to their intended targets. This study introduces two distinct strategies for loading a cardio-specific mimetic peptide (MP), previously designed to modulate L-type calcium channel function in cardiomyocytes, onto calcium phosphate nanoparticles (CaP NPs). MP-loaded CaP NPs were prepared by two different wet precipitation syntheses, one of which involved the use of sodium polyacrylate as a templating agent. Characterization of MP-loaded CaP NPs showed that their crystallinity, size, surface charge, and morphology could be tuned by adjusting the synthesis parameters. In vitro tests on cardiac cells confirmed that both types of MP-loaded CaP NPs are biocompatible with HL-1 cardiomyocytes and restored intracellular calcium flux under stressed conditions, highlighting their therapeutic potential. These results pave the way for further optimization of CaP NP formulations and suggest their potential as a viable nanomaterial for CVD treatment.
心血管疾病(CVDs)仍然是全球范围内主要的死亡原因,这凸显了对新治疗策略的迫切需求。基于肽的疗法已显示出治疗心血管疾病的巨大潜力;然而,它们在生理流体中的稳定性有限,这阻碍了其临床应用。为了克服这一挑战,有效的药物递送系统对于保护肽并将其有效地运输到预期靶点至关重要。本研究介绍了两种不同的策略,将先前设计用于调节心肌细胞中L型钙通道功能的心脏特异性模拟肽(MP)负载到磷酸钙纳米颗粒(CaP NPs)上。通过两种不同的湿沉淀合成方法制备了负载MP的CaP NPs,其中一种方法使用聚丙烯酸钠作为模板剂。对负载MP的CaP NPs的表征表明,通过调整合成参数可以调节其结晶度、大小、表面电荷和形态。对心脏细胞的体外测试证实,两种类型的负载MP的CaP NPs都与HL-1心肌细胞具有生物相容性,并在应激条件下恢复了细胞内钙通量,突出了它们的治疗潜力。这些结果为进一步优化CaP NP制剂铺平了道路,并表明它们作为治疗心血管疾病的可行纳米材料的潜力。